Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$75,957.00-5.31%ETH$2,238.34-7.69%GOLD$4,097.60+0.60%OIL$90.57+2.78%
Smart Investors Daily
SID Premium
BC

NASDAQ · BCTXZ

BriaCell Therapeutics Corp. Warrant

Healthcare · Biotechnology

$0.11

Up+$0.04 (+32.72%)

Updated Nov 5, 2026, 8:08 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
753.16K
P/E ratio
-1.99
Dividend yield
0.00%
52-week range
$0.06 – $0.33
Volume
269
Avg. volume
21.5K

Price performance · BCTXZ

BCTXZ price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

BCTXZ closed at $0.11 after 20 trading sessions, down 53.96% for the selected period.

Last close
$0.11
Period change
-53.96%
Period low
$0.11
Period high
$0.25
Daily close
View OHLC price history
BCTXZ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$0.1146$0.1146$0.1146$0.1146269
Nov 3, 2026$0.1101$0.1102$0.1101$0.1102298.05
Nov 2, 2026$0.1255$0.1255$0.11$0.1228.9K
Oct 30, 2026$0.127$0.127$0.1201$0.123614.11K
Oct 29, 2026$0.15$0.1582$0.15$0.15601
Oct 27, 2026$0.1398$0.1451$0.125$0.13510.29K
Oct 26, 2026$0.1398$0.14$0.122$0.1222K
Oct 23, 2026$0.1402$0.1402$0.1402$0.1402465
Oct 22, 2026$0.157$0.157$0.14$0.1436.43K
Oct 21, 2026$0.1607$0.165$0.1401$0.15720.2K
Oct 20, 2026$0.20$0.20$0.1607$0.160820.9K
Oct 19, 2026$0.19$0.2062$0.19$0.20621.41K
Oct 16, 2026$0.2088$0.2088$0.2085$0.2085483.54
Oct 15, 2026$0.175$0.175$0.155$0.156511.21K
Oct 14, 2026$0.20$0.20$0.1501$0.1717.11K
Oct 13, 2026$0.21$0.21$0.2001$0.20075.04K
Oct 12, 2026$0.2284$0.25$0.204$0.21543.09K
Oct 9, 2026$0.251$0.251$0.211$0.21114.79K
Oct 8, 2026$0.25$0.25$0.25$0.25100
Oct 7, 2026$0.284$0.30$0.2293$0.24899.12K

Latest BCTXZ news

The latest Smart Investors Daily articles mentioning BCTXZ.

Stock researchCompany · Overview

BCTXZ research

Overview

Company profile and research snapshot.

Company profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the BriaCell regimenFindings from a prospective pooled analysis of 111 heavily pretreated metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapiesPooled analysis includes patients from mul

Yahoo · Oct 6, 2026

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentati

Yahoo · Sep 14, 2026

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Independent DSMB reports no safety concerns to date and recommends continuing BriaCell's pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitorSeventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell's novel immunotherapy approachPhase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOB

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By